Application of finasteride during ipratropium bromide treatment in the elderly with chronic obstructive pulmonary disease
10.3760/cma.j.issn.0254-9026.2011.12.006
- VernacularTitle:非那雄胺在老年慢性阻塞性肺疾病患者异丙托溴铵治疗中的应用
- Author:
Tian WEI
- Publication Type:Journal Article
- Keywords:
Testosterone 5-alpha reductase;
Cholinergic antagonists;
Pulmonary diseases,chronic obstructive
- From:
Chinese Journal of Geriatrics
2011;30(12):1003-1004
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the application of finasteride during ipratropium bromide treatment in the elderly with chronic obstructive pulmonary disease. Methods The 263 patients who were hospitalized for chronic obstructive pulmonary disease (COPD) and treated with ipratropium bromide (aged 63-89 years) in Cadre Wards of Ji Shui Tan Hospital from Jan.2006 to Jan.2011 were reviewed.They were divided by gender and combination of benign prostatic hyperplasia (BPH) and treatment of finasteride.The duration of ipratropium bromide treatment,time to dysuria and the severe degree of dysuria were evaluated.Results None of the female patients suffered from difficult urination or discontinued impratropium bromide for abnormal urination,while there were 23.3％ cases with difficult urination,5.8％ catheterization and 3.4％ discontinued bromide in male patients.More patients suffered from catheterization and bromide discontinuance in prostatic hyperplasia group (8.0 ％ and 4.7 ％ ) as compared with non-prostatic hyperplasia group (P＜ 0.05).The occurrence of urethral catheterization for dysuria or ipratropium bromide discontinuance obviously decreased 40％ and 30％,respectively,after finasteride treatment (P＜0.01). Conclusions The COPD patients complicated with BPH should be treated with finasteride to prevent the occurrence of abnormal urination and urinary retention during the treatment of ipratropium bromide.
